Colorectal Cancer
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada
The first-in-human study is designed to assess both the gallium-68-labeled imaging agent and the lutetium-177-labeled therapeutic in five solid cancer types.
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.
Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer
The firm is evaluating its TCR-T cell therapy, engineered with the Sleeping Beauty transposon/transposase system, for solid tumors with certain hotspot mutations.Â